MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: lrb who wrote (626)	2/2/1998 4:12:00 PM
From: seminole	Read Replies (2) of 1826

Irb From: Annual Report 1996 "MGI 114 is the lead compound from a family of promising anti-tumor agents called aclyfulvenes." Maybe, we should purchase this stock until the number of brokers following the compnay exceeds the number of promissing acylfulvene compounds. richard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next